Saarland University Medical Center and Saarland University Faculty of Medicine
Internal Medicine IV - Nephrology and Hypertension
Director: Univ.-Professor Dr. Danilo Fliser
You are here: >> Startseite >> Klinische Zentren und Einrichtungen >> Departments and Institutes >> Medizinische Kliniken >> Internal Medicine IV

Internal Medicine IV - Nephrology and Hypertension

 

Director:

Prof. Dr. Danilo Fliser

 

Tel.: +49 6841/16-23526
Fax:  +49 6841/16-23540

 

 

 

 

 

 

The Department of Internal Medicine IV provides medical care for patients suffering from renal disease and hypertension. The department, which has been in existence for many years, is also home to the only university chair in nephrology in Saarland and Rhineland Palatinate. Equipped with advanced medical technology, our department is able to provide the highest quality diagnostic and therapeutic interventions for patients with renal and hypertensive disorders. We also run risk-factor consultation sessions to teach preventive strategies concerning in particular: hypertension, fat metabolism, excess weight, sedentary lifestyles, stress and medication. Patients found to be already suffering from advanced renal insufficiency will receive expert advice and, where necessary, will undergo kidney replacement therapy such as haemodialysis, peritoneal dialysis or kidney transplantation. Transplantations are carried out in cooperation with the Department of Urology. Besides receiving professional inpatient treatment, patients are also supervised in our numerous specialist consulting sessions. The research carried out at the department is mainly focused on cardiovascular complications in cases of chronic renal insufficiency, and infection monitoring in immunosuppressed patients. Our research programmes are supported by the German Research Council (DFG), the Else Kröner-Fresenius Foundation, the German José Carreras Leukaemia Foundation and other project-specific funds.

 

Cooperations

SysKid Wissenschaftliches Institut für Nephrologie European Uremic Toxin Work Group European Renal and Cardiovascular Medicine

New Paper

Zewinger S, Kleber ME, Tragante V, McCubrey RO, Schmidt AF, Direk K, Laufs U, Werner C, Koenig W, Rothenbacher D, Mons U, Breitling LP, Brenner H, Jennings RT, Petrakis I, Triem S, Klug M, Filips A, Blankenberg S, Waldeyer C, Sinning C, Schnabel RB, Lackner KJ, Vlachopoulou E, Nygard O, Svingen GFT, Pedersen ER, Tell GS, Sinisalo J, Nieminen MS, Laaksonen R, Trompet S, Smit RAJ, Sattar N, Jukema JW, Groesdonk HV, Delgado G, Stojakovic T, Pilbrow AP, Cameron VA, Richards AM, Doughty RN, Gong Y, Cooper-DeHoff R, Johnson J, Scholz M, Beutner F, Thiery J, Smith JG, Vilmundarson RO, McPherson R, Stewart AFR, Cresci S, Lenzini PA, Spertus JA, Olivieri O, Girelli D, Martinelli NI, Leiherer A, Saely CH, Drexel H, Mundlein A, Braund PS, Nelson CP, Samani NJ, Kofink D, Hoefer IE, Pasterkamp G, Quyyumi AA, Ko YA, Hartiala JA, Allayee H, Tang WHW, Hazen SL, Eriksson N, Held C, Hagstrom E, Wallentin L, Akerblom A, Siegbahn A, Karp I, Labos C, Pilote L, Engert JC, Brophy JM, Thanassoulis G, Bogaty P, Szczeklik W, Kaczor M, Sanak M, Virani SS, Ballantyne CM, Lee VV, Boerwinkle E, Holmes MV, Horne BD, Hingorani A, Asselbergs FW, Patel RS, Kramer BK, Scharnagl H, Fliser D, Marz W, Speer T.

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

Lancet Diabetes Endocrinol. 2017;5(7):534-543. Impact factor: 19.7 Abstract Comment


Heine GH, Rogacev KS, Weingartner O, Marsche G.

Still a reasonable goal: Targeting cholesterol in dialysis and advanced chronic kidney disease patients.

Semin Dial. 2017. Impact factor: 1.7 Abstract


Zawada AM, Zhang L, Emrich IE, Rogacev KS, Krezdorn N, Rotter B, Fliser D, Devaux Y, Ziegler-Heitbrock L, Heine GH.

Reprint of: MicroRNA profiling of human intermediate monocytes.

Immunobiology. 2017;222(6):831-840. Impact factor: 2.7 Abstract

Building 40.2

EURECA-m

Newsletter